Cardiac Care Backed By Stanford StartX and JLABS
With 39 devices successfully implanted, we’ve collected over 60,000 hours of cardiac data. Incubated and accelerated by Johnson & Johnson's JLABS and Stanford StartX, we’re ready to pursue FDA clearance and move toward commercialization.
Join us in transforming cardiac monitoring with innovative, AI-powered implantable devices.
This Reg CF offering is made available through StartEngine Primary, LLC, a member of FINRA/SPIC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
By clicking "Get Updates", you consent to receive marketing text messages (e.g. promos, cart reminders) from StartEngine Crowdfunding, Inc. at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms
$14M raised from 10,000+ investors
Founded in 2019, Future Cardia aims to revolutionize cardiac care with our innovative, implantable device. This cutting-edge technology enables near real-time, continuous heart monitoring, leading to early detection, proactive intervention, and improved patient outcomes.
Extensive Data Collection
Over 60,000 hours of real-world cardiac data collected.
Clinical Trial Progress
Advancing towards clinical trials to validate device efficacy, moving towards commercialization.
Successful Implantations
39 devices successfully implanted in patients.
Regulatory Compliance
Preparing for FDA 510(k) submission to bring our device to market.
Future Cardia is at the forefront of cardiac health technology, with a mission to improve lives and transform cardiac care.
Invest
Backed by the Best and Biggest Names in Science
Our commitment to innovation is reinforced by collaborations with leading institutions:
A 2-Minute Procedure for Better Heart Health
Our minimally-invasive device provides continuous, real-time data, enabling early detection of potential complications and proactive interventions.
Implantable Device
A minimally invasive procedure to implant a small, long-lasting device.
Continuous Monitoring
Near real-time tracking of vital heart metrics, including ECG, heart and lung sounds, and patient movement.
Deep data analytics
Advanced AI algorithms analyze data to identify potential issues early on.
Remote Monitoring
Securely transmit data to healthcare providers for remote monitoring and timely interventions.
60,000+ Hours of Data Collected
Future Cardia aims to redefine cardiac monitoring with a simple, two-minute implant procedure that transforms heart health management. This implantable, under-the-skin device delivers continuous, near real-time cardiac monitoring, offering early detection and intervention for patients with chronic cardiac conditions.
Invest
39 Devices Successfully Implanted
Key Benefits of Future Cardia's Implantable Device
Superior Accuracy
Outperforms wearables and other cardiac devices as current monitoring methods are often limited and invasive.
early detection
Outperforms wearables and other cardiac devices as current monitoring methods are often limited and invasive.
Data-Driven
Over 70,000 hours of data– the longest, most comprehensive cardiac data to date.
Reduced Hospitalizations
Lowers the risk of unnecessary hospital stays and reduces hospitalization risks.
Enhanced Patient Outcomes
Improves patient quality of life and overall health.
Long-term Solution
2-year battery for long-term monitoring solution.
Cost-Effective Healthcare
Reduces healthcare costs through preventative care.
Key anticipated Benefits of Future Cardia's Implantable Device
Accessible
A long-term solution that we believe could provide more accessible results than other cardiac devices.
early detection
Using multi-sensor technology, the device continuously gathers critical data, enabling remote monitoring and timely interventions– detecting early signs of potential issues.
Data-Driven
Over 60,000 hours of data– the longest, most comprehensive cardiac data to date.
Reduced Hospitalizations
Could lower the risk of unnecessary hospital stays and reduce hospitalization risks.
Enhanced Patient Outcomes
Improves patient quality of life and overall health.
Long-term Solution
2-year battery for long-term monitoring solution.
Cost-Effective Healthcare
Reduces healthcare costs through preventative care.
deep analytics Insights
Secure Data Transmission and Access
Near Real-Time Cardiac Monitoring
Future Cardia's implantable device continuously tracks 3 vital heart metrics:
- ECG: Monitors the heart's electrical activity.
- Heart and Lung Sounds: Detects abnormalities in heart and lung function.
- Patient Movement: Tracks physical activity levels.
cardiac complications cost $40b in the us
Heart disease, heart failure, and cardiac arrhythmia affect billions, costing over $40 billion annually. These complex and challenging conditions lead to hospitalizations, which places a significant burden on healthcare systems. And current monitoring methods are limited, invasive, and costly, leaving a gap in proactive cardiac care.
As the global cardiac monitoring market, currently valued at $65 billion, continues to grow, we believe Future Cardia is on a path to revolutionize cardiac care and significantly impact patient lives.
significant Market Potential
Market Size $914 million in 2023
Projected Growth 6.6% CAGR to reach $1.6 billion by 2031
Market Size $3.42 billion in 2023
Projected GrowthExpected to reach $9.75 billion by 2033
Market Size $4.9 billion in 2021
Projected Growth Expected to reach $14.9 billion by 2031
Over 200 Years of Combined Expertise
From Medtronic, Boston Scientific, and Stanford.
Our team brings together over 200 years of combined experience from industry leaders with extensive expertise in cardiology and medical device development.
Cardiology & medtech startup trailblazer. 20+ years of experience in clinical, business and tech operations at Silicon Valley startups as well as Medtronic and Abiomed. $13M raised from angel investors. Northwestern University, Kellogg School of Management MBA.
Biomedical engineer & AI maestro. Neuro-modulations and machine learning expert. Leading AI innovations at Oracle (NYSE: ORCL). Stanford University PhD.
Medtech leader & regulation guru. R&D, manufacturing, quality, and regulatory expert with 21 years experience. Specializes in navigating regulatory pathways to lead teams to market. University of Minnesota, Biomedical Engineering.
Medical device R&D veteran. 20+ years of experience. Expert in systems development and AI applications. Led the development of Coloplast's first active implantable neuromodulation device. University of Minnesota BEE, University of St. Thomas MSDD.
Heart health expert & seasoned medtech scientist. 25+ years of expertise in heart failure and cardiac hemodynamics. Former Chief Science Officer at Sunshine Heart Inc. (NASDAQ: SSH). Johns Hopkins University PhD.
World-renowned cardiologist & scientist. Leader in heart failure and medtech startups with multiple exits. Former VP at Heartware ($1.2B acquisition by Medtronic). Columbia University MD PhD.
Leading cardiologist & electrophysiology, currently Associate Professor at Harvard Medical School Special focus on treating cardiac arrhythmias at Mass General Hospital in Boston. Stanford University MD PhD.
$14M raised from 10,000+ investors
With Future Cardia, we're empowering healthcare providers to deliver superior patient care and transforming the landscape of heart health. Join us in transforming cardiac care.
Invest in the future of cardiac care with Future Cardia.
Invest
Exclusive Investor Perks
Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Hylio.
Venture Club Members 
earn 10% bonus on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Future Cardia.
Loyalty Bonus - All previous investors will receive 5% bonus shares.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Venture Club bonus and the Loyalty Bonus and the Reservations Bonus in addition to the aforementioned bonus.
Voting Rights of Securities Sold in this Offering - Voting Proxy‍
Each Investor in this offering shall appoint the Chief Executive Officer of the Company, or his or her successor, as their proxy and attorney-in-fact, granting full authority to vote securities, handle communications, execute documents, and take necessary actions on their behalf, with this proxy surviving personal or corporate changes. Please review the offering materials for full information.
Venture Club Members 
earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
Join the Discussion
Learn How A 2 Minute Procedure Can Save Lives
By clicking "Get Updates", you consent to receive marketing text messages (e.g. promos, cart reminders) from StartEngine Crowdfunding, Inc. at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms
